Protocol for the Study of Heart and Renal Protection-Extended Review: Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort

Louisa Sukkar, Ben Talbot, Min Jun, Erika Dempsey, Robert Walker, Lai Hooi, Alan Cass, Meg Jardine, Martin Gallagher, Louisa Sukkar, Ben Talbot, Min Jun, Erika Dempsey, Robert Walker, Lai Hooi, Alan Cass, Meg Jardine, Martin Gallagher

Abstract

Background: There are limited studies on the effects of statins on outcomes in the moderate chronic kidney disease (CKD) population and their trajectory to end-stage kidney disease.

Objective: To examine the long-term effects of lipid-lowering therapy on all-cause mortality, cardiovascular morbidity, CKD progression, and socioeconomic well-being in Australian, New Zealand, and Malaysian SHARP (Study of Heart and Renal Protection) trial participants-a randomized controlled trial of a combination of simvastatin and ezetimibe, compared with placebo, for the reduction of cardiovascular events in moderate to severe CKD.

Design: Protocol for an extended prospective observational follow-up.

Setting: Australian, New Zealand, and Malaysian participating centers in patients with advanced CKD.

Patients: All SHARP trial participants alive at the final study visit.

Measurements: Primary outcomes were measured by participant self-report and verified by hospital administrative data. In addition, secondary outcomes were measured using a validated study questionnaire of health-related quality of life, a 56-item economic survey.

Methods: Participants were followed up with alternating face-to-face visits and telephone calls on a 6-monthly basis until 5 years following their final SHARP Study visit. In addition, there were 6-monthly follow-up telephone calls in between these visits. Data linkage to health registries in Australia, New Zealand, and Malaysia was also performed.

Results: The SHARP-Extended Review (SHARP-ER) cohort comprised 1136 SHARP participants with a median of 4.6 years of follow-up. Compared with all SHARP participants who originally participated in the Australian, New Zealand, and Malaysian regions, the SHARP-ER participants were younger (57.2 [48.3-66.4] vs 60.5 [50.3-70.7] years) with a lower proportion of men (61.5% vs 62.8%). There were a lower proportion of participants with hypertension (83.7% vs 85.0%) and diabetes (20.0% vs 23.5%).

Limitations: As a long-term follow-up study, the surviving cohort of SHARP-ER is a selected group of the original study participants, which may limit the generalizability of the findings.

Conclusion: The SHARP-ER study will contribute important evidence on the long-term outcomes of cholesterol-lowering therapy in patients with advanced CKD with a total of 10 years of follow-up. Novel analyses of the socioeconomic impact of CKD over time will guide resource allocation.

Trial registration: The SHARP trial was registered at ClinicalTrials.gov NCT00125593 and ISRCTN 54137607.

Keywords: chronic renal insufficiency; disease progression; follow-up studies; income; myocardial infarction; poverty; statins.

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

© The Author(s) 2019.

Figures

Figure 1.
Figure 1.
Flow diagram of participants available for SHARP-ER outcomes. Note. SHARP = Study of Heart and Renal Protection; SHARP-ER = Study of Heart and Renal Protection-Extended Review. aOther: noncompliance to study visits n = 8; physician discretion n = 7. *MAE = major atherosclerotic events; MVE = major vascular events.
Figure A1.
Figure A1.
SHARP trial profile.

References

    1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339-352.
    1. Cass AC, Gallagher MP, Howard J, McDonald S, Snelling P, White SL. The Economic Impact of End-stage Kidney Disease in Australia: Projections to 2020. Melbourne, VIC, Australia: Kidney Health Australia; 2010.
    1. Australia and New Zealand Dialysis and Transplant Registry. ANZDATA Report 2013. Adelaide, SA, Australia: ANZDATA Registry; 2013.
    1. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034-2047.
    1. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. Kidney Int. 2011;80(1):93-104.
    1. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-248.
    1. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-1407.
    1. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of Fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024-2031.
    1. SHARP Collaborative Group. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-2192.
    1. Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378(9808):2013-2020.
    1. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359(9315):1379-1387.
    1. Lloyd SM, Stott DJ, deCraen AJ, et al. Long-term effects of Statin treatment in elderly people: extended follow-up of the prospective Study of Pravastatin in the elderly at risk (PROSPER). PLoS ONE. 2013;8(9):e72642.
    1. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol. 2000;86(3):257-262.
    1. Ford I, Murray H, McCowan C, Packard CJ. Long term safety and efficacy of lowering LDL cholesterol with Statin therapy: 20-year follow-up of west of Scotland coronary prevention study. Circulation. 2016;133(11):1073-1080.
    1. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving Fluvastatin: the ALERT extension study. Am J Transplant. 2005;5(12):2929-2936.
    1. The German Diabetes and Dialysis Study Investigators. Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int. 2016;89(6):1380-1387.
    1. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785-794.e10.
    1. EuroQol—A new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
    1. Grootaert C, Narayan D, Jones VN, Woolcock M. Measuring Social Capital: An Integrated Questionnaire (World bank working paper). Washington, DC: The World Bank; 2004.
    1. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception Questionnaire. J Psychosom Res. 2006;60(6):631-637.
    1. Survey of Income and Program Participation (SIPP). Washington, DC: DUCB; 2010. . Accessed September 20, 2016.
    1. Australian Institute of Health and Welfare. National death index 2016. . Accessed January 28, 2019.
    1. Australian and New Zealand dialysis and transplant registry 2016. . Accessed January 28, 2019.
    1. Medicare benefits schedule 2017. . Accessed January 28, 2019.
    1. Pharmaceutical benefits scheme 2016. . Accessed January 28, 2019.
    1. De Vos K, Zaidi MA. Equivalence scale sensitivity of poverty statistics for the Member States of the European Community. Rev Income Wealth. 1997;43(3):319-333.
    1. Jeon Essue B, Jan S, Wells R, Whitworth JA. Economic Hardship associated with managing chronic illness: a qualitative inquiry. BMC Health Serv Res. 2009;9:182-111.
    1. Jan S, Lee SWL, Sawhney JPS, et al. Catastrophic health expenditure on acute coronary events in Asia: a prospective study. Bull World Health Organ. 2016;94(3):193-200.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться